NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.49 -0.16 (-3.44 %)
(As of 07/17/2018 04:11 AM ET)
Previous Close$4.65
Today's Range$4.40 - $4.67
52-Week Range$3.22 - $7.95
Volume269,700 shs
Average Volume640,378 shs
Market Capitalization$139.79 million
P/E Ratio-7.62
Dividend YieldN/A
Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.57
Current Ratio2.41
Quick Ratio2.41


Trailing P/E Ratio-7.62
Forward P/E Ratio-6.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.38 million
Price / Sales3.81
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book4.83


EPS (Most Recent Fiscal Year)($0.61)
Net Income$-17,390,000.00
Net Margins-49.30%
Return on Equity-64.30%
Return on Assets-21.67%


Outstanding Shares30,060,000
Market Cap$139.79

The Truth About Cryptocurrencies

Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The biotechnology company had revenue of $9.74 million for the quarter, compared to analysts' expectations of $8.88 million. Conatus Pharmaceuticals had a negative return on equity of 64.30% and a negative net margin of 49.30%. View Conatus Pharmaceuticals' Earnings History.

When is Conatus Pharmaceuticals' next earnings date?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

What price target have analysts set for CNAT?

6 Wall Street analysts have issued 12 month price objectives for Conatus Pharmaceuticals' shares. Their predictions range from $4.30 to $20.00. On average, they anticipate Conatus Pharmaceuticals' share price to reach $12.1414 in the next twelve months. This suggests a possible upside of 170.4% from the stock's current price. View Analyst Ratings for Conatus Pharmaceuticals.

What is the consensus analysts' recommendation for Conatus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 1,612,627 shares, a decrease of 32.0% from the June 15th total of 2,372,503 shares. Based on an average daily volume of 809,565 shares, the short-interest ratio is presently 2.0 days. Currently, 6.1% of the shares of the company are sold short. View Conatus Pharmaceuticals' Current Options Chain.

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)
  • Mr. Daniel L. Ripley, Sr. VP of Bus. Devel., Program & Alliance Management (Age 57)

Has Conatus Pharmaceuticals been receiving favorable news coverage?

News stories about CNAT stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Conatus Pharmaceuticals?

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $4.49.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $139.79 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]

MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Featured Article: Earnings Per Share (EPS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.